Astrazeneca Pharma India Reports Strong Financial Results, Highlights Operational Efficiency and Profitability in March 2025
Astrazeneca Pharma India reported strong financial results for the quarter ending March 2025, with net sales of Rs 480.48 crore and an operating profit of Rs 86.37 crore, the highest in five quarters. Profit after tax reached Rs 62.47 crore, reflecting significant profitability and operational efficiency.
Astrazeneca Pharma India has reported its financial results for the quarter ending March 2025, showcasing a robust performance in the pharmaceuticals and biotechnology sector. The company achieved net sales of Rs 480.48 crore, marking a consistent upward trend over the last five quarters. This positive trajectory is further reflected in the operating profit, which reached Rs 86.37 crore, the highest in the same period, indicating enhanced operational efficiency.The operating profit margin also saw a notable achievement, standing at 17.98%, underscoring the company's effective cost management strategies. Profit before tax (PBT) was recorded at Rs 68.00 crore, while profit after tax (PAT) reached Rs 62.47 crore, both figures representing the highest levels in the last five quarters. The PAT growth of 39.5% compared to the average of the previous four quarters highlights Astrazeneca Pharma's strong profitability.
Earnings per share (EPS) also reached a peak of Rs 23.30, reflecting the company's commitment to delivering value to its shareholders. However, it is worth noting that the increase in non-operating income, recorded at Rs 16.15 crore, may not be sustainable in the long term.
Overall, Astrazeneca Pharma India has experienced evaluation changes that reflect its strong financial standing in the current quarter.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
